Shen, Jiacheng
Wu, Li
Shi, Xiaoying
Chen, Gang
Liu, Tingwei
Xu, Fangfang
Xu, Xiaocui
Kou, Xiaochen
Zhao, Yanhong
Wang, Hong
Wang, Chenfei
Gao, Shaorong
Xu, Shaohua http://orcid.org/0000-0001-9810-1325
Funding for this research was provided by:
National Natural Science Foundation of China (32270840)
Natural Science Foundation of Shanghai Municipality (21ZR1450900)
Article History
Received: 22 November 2023
Accepted: 7 February 2024
First Online: 5 March 2024
Declarations
:
: Informed consents were obtained from all participants, and the study protocol in this study was approved by the Medical Ethics Committee of Shanghai First Maternity and Infant Hospital in Tongji University on 17th July 2019 (Title: “Clinical study of human umbilical cord mesenchymal stem cells in treatment of premature ovarian failure and endometrial repair”, Ethics number: KS1956). Animal experiments in this study were approved by Animal Ethics Committee of Tongji University on 20th November 2022 (Title: “Transplantation of LRP1<sup>high</sup> UC-MSCs subsets improves ovarian function and improves POF treatment”, Ethics number: TJAB03223124). All experiments were conducted in compliance with the ARRIVE guidelines.
: Not applicable.
: The authors have declared that no competing interests exist.